Regencell Bioscience Holdings Limited (NASDAQ:RGC) experienced a sharp decline on Thursday morning, falling 6.6% to $7.50 as of 9:53 a.m. EDT, despite an earlier intraday high of $9.31. The stock remains deeply underwater compared to its May registered direct offering price of $20.30, trading approximately 63.1% below that level.
The drop occurred against a backdrop of rising biotech exchange-traded funds. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) gained 1.9%, the SPDR S&P Biotech ETF (NYSEARCA:XBI) rose 2.3%, and the Invesco QQQ Trust (NASDAQ:QQQ) added 0.7%. Regencell's performance diverged sharply from the sector trend.
On Wednesday, July 1, Regencell shares had closed at $8.03, up 31.86% on volume of 2.57 million shares, following a close of $6.09 on June 30. However, Thursday's trading saw a wide intraday range of 25.1%, fluctuating between $7.44 and $9.31, with 282,403 shares changing hands by late morning.
The key metric remains the May registered direct offering. On May 22, Regencell closed the sale of 985,222 ordinary shares at $20.30 per share, raising approximately $20.0 million in gross proceeds. A new large institutional investor contributed $19 million as the lead, with Univest Securities acting as the sole placement agent. The current price of $7.50 represents a 63.1% decline from that offering price, and even Thursday's intraday high of $9.31 left shares 54.1% below the sale price.
Regencell is an early-stage biotechnology company focused on traditional Chinese medicine treatments for ADHD and autism spectrum disorder. According to its annual report, the company has no approved products and has not generated any revenue from product sales. For the six months ended December 31, 2025, Regencell reported a net loss of $5.3 million, up from $1.85 million in the prior-year period, with research and development expenses totaling just $416,030.
The company disclosed in its annual report that it received a subpoena and correspondence from the U.S. Department of Justice following recent volatility in its ordinary shares. The DOJ is investigating trading activity in Regencell's shares, and the company stated it is cooperating fully, expecting ongoing legal and other costs related to the probe. These costs have already impacted financials: general and administrative expenses jumped to $4.9 million for the six months ended December 31, 2025, from $1.5 million a year earlier, with about $2.3 million of that increase attributed to higher professional fees tied to legal and investigation matters.
CEO Yat-Gai Au holds a beneficial ownership stake of 88.6%, according to the annual report. Google Finance lists 495.47 million shares outstanding, giving the company an estimated equity value of approximately $3.72 billion at $7.50 per share.
As of Thursday morning, Regencell had not issued any new press releases since the May 19 registered direct offering notice. The recent price and volume movements occurred without any company statement. U.S. stock markets are scheduled to close on Friday, July 3, for the Independence Day holiday, with Nasdaq operating normal hours on Thursday.
